RTEP 7: Prof. Sébastien Thureau
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small cell lung cancer, based on residual tumor uptake on [¹⁸F]FDG-PET at 42 Gy (RTEP7–IFCT-1402): a multicenter phase 2 randomized controlled trial.
The publication titled "Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small cell lung cancer" describes a multicenter phase 2 randomized controlled trial aimed at evaluating the safety and efficacy of escalating the radiotherapy dose up to 74 Gy, based on residual tumor uptake on [¹⁸F]FDG-PET after 42 Gy, in patients with inoperable stage III non-small cell lung cancer (NSCLC).
The trial included 158 patients and showed that dose escalation led to a higher local control rate at 15 months compared to the standard 66 Gy treatment, without a significant increase in adverse effects. The results suggest that this adaptive approach could improve local control without additional toxicity, warranting further evaluation in a phase 3 trial.
About Pr. Sébastien Thureau
Sébastien Thureau is a physician-researcher specializing in radiation oncology and nuclear medicine, serving as a Professor and Hospital Practitioner at the Henri-Becquerel Center in Rouen. An expert in functional imaging and stereotactic radiotherapy, he conducts research to personalize cancer treatments. Actively involved in teaching and professional societies, he is an inspiring figure in the field of oncology.